Kalundborg, Denmark, faces challenges despite Novo Nordisk's $8.5 billion investment in Wegovy.

Kalundborg, Denmark, home to 16,000 residents, is the main production center for the weight loss drug Wegovy, manufactured by Novo Nordisk, which has invested over $8.5 billion in the town. Despite this investment, Kalundborg faces challenges like underperforming schools, limited amenities, and high commuting among workers, leading to traffic issues known as the "Novo Queue." The mayor remains optimistic, noting the creation of over 1,000 new jobs annually.

November 03, 2024
9 Articles